1. Home
  2. GPRO vs LYEL Comparison

GPRO vs LYEL Comparison

Compare GPRO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$1.31

Market Cap

119.4M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$11.02

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRO
LYEL
Founded
2004
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.4M
320.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
GPRO
LYEL
Price
$1.31
$11.02
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
70.1M
88.6K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
79.08
N/A
EPS
N/A
N/A
Revenue
$651,542,000.00
$36,000.00
Revenue This Year
$23.14
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$10.46
52 Week High
$3.05
$45.00

Technical Indicators

Market Signals
Indicator
GPRO
LYEL
Relative Strength Index (RSI) 57.87 27.52
Support Level $0.65 N/A
Resistance Level $1.70 $15.38
Average True Range (ATR) 0.26 0.77
MACD -0.01 -0.39
Stochastic Oscillator 47.23 2.56

Price Performance

Historical Comparison
GPRO
LYEL

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: